Integrated Filing (Financial) for the quarter and financial year ended on 31st March, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jenburkt Pharmaceuticals reported FY25 revenue from operations of Rs 151.69 crore, up about 6.8% from Rs 141.97 crore in FY24. Profit after tax rose to Rs 32.06 crore from Rs 25.98 crore, a growth of roughly 23.4%. Q4 revenue came in at Rs 41.05 crore versus Rs 38.84 crore a year earlier, with Q4 PAT at Rs 8.54 crore versus Rs 7.88 crore. EPS for the year stood at Rs 72.65 versus Rs 58.86 previously. Operating cash flow strengthened sharply to Rs 27.91 crore from Rs 8.12 crore, and the board declared a dividend during the year. Capital work-in-progress jumped to Rs 40.28 crore from Rs 1.24 crore, pointing to ongoing capacity expansion.
Earnings growth significantly outpaced revenue growth, reflecting margin expansion backed by stronger cash generation. Healthy reserves, low debt and continued capex suggest the company is self-funding growth, which is supportive for shareholders.